How to buy Aeterna Zentaris (AEZS) stocks

Learn how to easily invest in Aeterna Zentaris stocks.

Aeterna Zentaris is a biotechnology business based in Canada. Aeterna Zentaris shares (AEZS) are listed on the Toronto Stock Exchange (TSX) and all prices are listed in Canadian Dollars.

Our top picks for where to buy Aeterna Zentaris stock

Best for Beginners

Go to site
Easy to use app
  • $200 or more cash back offer
  • Get 100 free trades
  • Best platform for beginners

Best Overall

Go to site
Low margin rates
  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Best for Low Fees

Go to site
CA & US trading
  • 6% cash rebate plus $2,200 in trading perks
  • Low transaction fees
  • Easy-to-use app

How to buy Aeterna Zentaris stock

  1. Choose a stock trading platform. Compare investment platforms.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – AEZS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Aeterna Zentaris stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Product CAFST Finder Score Available Asset Types Account Types Stock Trading Fee Account Fee Offer
Interactive Brokers logo
Finder Score
Stocks, Bonds, Options, Index Funds, ETFs, Currencies, Futures
RRSP, TFSA, Personal, Joint
min $1.00, max 0.5%
$0
CIBC logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, Precious Metals, IPOs
RRSP, RESP, RRIF, TFSA, Personal, Joint
$6.95
$0 if conditions met, or $100
Get 100 free trades when you open a CIBC Investor’s Edge account using promo code EDGE2425. Plus, get $200 or more cash back. Valid until March 31, 2025.
Moomoo logo
Finder Score
Stocks, Options, ETFs
RRSP, TFSA, Personal
$0.014/stock
$0
Enjoy a 6% cash rebate, plus $2,200 in trading perks.
RBC Direct Investing logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, Precious Metals, IPOs
RRSP, RESP, RRIF, TFSA, Personal, Joint, Business
$6.95 - $9.95
$0 if conditions met, otherwise $25/quarter
Get a $300 cash bonus and up to 500,000 Avion points when you open your first eligible RBC Direct Investing account. Plus, get 50 commission-free trades to use within one year of account opening. Conditions apply. Offer ends March 3, 2025
Questrade logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, Forex, GICs, Precious Metals, IPOs
RRSP, RESP, RRIF, TFSA, Personal
$4.95 - $9.95
$0
Qtrade logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
RRSP, RESP, RRIF, TFSA, Personal, Joint
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get 1% cashback or more, a $150 sign-up bonus & unlimited free trades until April 30th, 2025.
loading

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Aeterna Zentaris stock price (Toronto Stock Exchange (TSX): AEZS)

Use our graph to track the performance of AEZS stocks over time.

Aeterna Zentaris stocks at a glance

Information last updated 2024-10-10.
52-week rangeC$4.64 - C$12.50
50-day moving average C$7.81
200-day moving average C$7.33
Wall St. target priceC$4.00
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) C$-3.18

Is it a good time to buy Aeterna Zentaris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeterna Zentaris financials

Revenue TTM C$2.4 million
Gross profit TTM C$5.2 million
Return on assets TTM -29.96%
Return on equity TTM -81.71%
Profit margin 0%
Book value C$10.68
Market Capitalization C$25.4 million
EBITDA C$-19,891,000

TTM: trailing 12 months

Aeterna Zentaris stock dividends

We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.

Have Aeterna Zentaris's stocks ever split?

Aeterna Zentaris's stocks were split on a 0.0236:1 basis on 6 June 2024 . So if you had owned 1 share the day before before the split, the next day you'd have owned 0.0236 shares. This wouldn't directly have changed the overall worth of your Aeterna Zentaris stocks – just the quantity. However, indirectly, the new 4137.3% higher stock price could have impacted the market appetite for Aeterna Zentaris stocks, which in turn could have impacted Aeterna Zentaris's stock price.

Aeterna Zentaris stock price volatility

Over the last 12 months, Aeterna Zentaris's stocks have ranged in value from as little as C$4.64 up to C$12.5. A popular way to gauge a stock's volatility is its "beta."

AEZS.TO volatility(beta: 2.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (TO average) beta is 1, while Aeterna Zentaris's is 2.257. This would suggest that Aeterna Zentaris's stocks are significantly more volatile than the average for this exchange and represent a higher risk.

Aeterna Zentaris overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.

Frequently asked questions

What percentage of Aeterna Zentaris is owned by insiders or institutions?
Currently 1.321% of Aeterna Zentaris stocks are held by insiders and 5.213% by institutions.
When does the fiscal year end for Aeterna Zentaris?
Aeterna Zentaris's fiscal year ends in December.
Where is Aeterna Zentaris based?
Aeterna Zentaris's address is: 222 Bay Street, Toronto, Canada, M5K 1E7
What is Aeterna Zentaris's ISIN number?
Aeterna Zentaris's international securities identification number is: CA0079754028
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site